| Dai Lichen,Gu Dayong,Yu Jingping.Advances in the clinical application of stereotactic body radiotherapy combined with immune checkpoint inhibitors for oligometastatic esophageal cancer[J].Chinese Journal of Radiological Medicine and Protection,2026,46(7):712-720 |
| Advances in the clinical application of stereotactic body radiotherapy combined with immune checkpoint inhibitors for oligometastatic esophageal cancer |
| Received:September 04, 2025 |
| DOI：10.3760/cma.j.cn112271-20250904-00316 |
| KeyWords:Stereotactic body radiotherapy Immune checkpoint inhibitor Esophageal cancer Oligometastasis |
| FundProject:上海市卫健委临床面上项目(202340160);常州市卫健委科技前沿技术项目(QY202404);南京医科大学常州医学中心项目(CMCC202411) |
| Author Name | Affiliation | E-mail | | Dai Lichen | Department of Radiation Oncology, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing 210000, China | | | Gu Dayong | Department of Radiation Oncology, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing 210000, China | | | Yu Jingping | Department of Radiation Oncology, Changzhou Cancer Hospital, Changzhou 213032, China | yujingping700420@sina.com |
|
| Hits: 1071 |
| Download times: 28 |
| Abstract:: |
| Esophageal cancer is a highly prevalent malignant tumor in China. Its oligometastatic state lies between localized disease and extensive metastasis, and has been regarded as an important window for clinical intervention in recent years. Currently, immune checkpoint inhibitors (ICIs) have become the first-line standard treatment for advanced esophageal cancer, but the clinical benefits for patients remain limited. Stereotactic body radiotherapy (SBRT) is characterized by high precision and high dose, which can not only achieve local control of oligometastatic lesions in esophageal cancer but also induce systemic antitumor immune responses. The two have a synergistic effect, and thus the combined application mode of SBRT and immunotherapy is becoming a research hotspot. This review focuses on the latest progress of SBRT combined with ICIs in the treatment of oligometastatic esophageal cancer, covering the evolution of the disease definition, potential synergistic mechanisms, and relevant studies, aiming to provide valuable references for clinical practice. |
| HTML View Full Text View/Add Comment Download reader |
| Close |
|
|
|
